CDKL5 Deficiency Disorder Market to Register Immense Growth During the Forecast Period (2022-2032), Asserts DelveInsight
Extensive research and development activities of pharmaceutical companies with drugs such as TAK-935/OV935 (Takeda and Ovid Therapeutics) and Ganaxolone (Marinus Pharmaceuticals), and others in clinical trials and their expected launch shall also fuel the growth of the market growth and the treatment scenario in the coming years.
DelveInsight’s “CDKL5 Deficiency Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the CDKL5 Deficiency Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The CDKL5 Deficiency Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
CDKL5 Deficiency Disorder: An Overview
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) caused by changes (mutations) in the CDKL5 gene. CDD has been classified as a DEE because the genetic change causes both epileptic activities as well as severe impairment of development. Previously known as serine/threonine-protein kinase 9 (STK9), CDKL5, and mutations in this gene were first identified as disease-causing in 2004.
The hallmarks of CDD are the onset of seizures at a very early age (usually about 3 months but can be as early as the first week of life) and severe neurodevelopmental delay impacting cognitive, motor, speech, and visual function. CDD can manifest in a broad range of clinical severity and is often associated with other symptoms such as gastrointestinal and sleep disturbances.
The core symptoms of CDD include epileptic seizures starting early in life, epileptic spasms often occurring without hypsarrhythmia, multiple different types of seizures, limited ability to walk, limited hand skills, lack of eye contact, constipation, sleep difficulties, intellectual disability, etc. Diagnosis is initially suspected based on clinical presentation and confirmed by molecular genetic testing for CDKL5 mutations or multigene panel testing for early-onset epilepsy.
CDKL5 Deficiency Disorder Market Key Facts
-
As per the “National Organization for Rare Disorders (NORD),” CDKL5 mutations have been identified in many ethnic groups, with more females than males being reported with an approximate ratio of 4:1.
-
As per Orpha.net, CDKL5-related epileptic encephalopathy has an estimated birth prevalence of 1/42,000 in the United Kingdom and affects more females with a sex ratio of 12:1.
-
As per the US National Library of Medicine, more than 1,000 cases have been reported worldwide.
-
According to the International Foundation for CDKL5 Research, although rare, the occurrence is believed to be ~1:40,000-60,000 live births, making it one of the most common forms of genetic epilepsy.
CDKL5 Deficiency Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted CDKL5 Deficiency Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the CDKL5 Deficiency Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
CDKL5 Deficiency Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the CDKL5 Deficiency Disorder Epidemiology, Segmented as –
-
Total Prevalent cases of CDKL5 Deficiency Disorder in the 7MM (2019–2032)
-
Gender-specific Prevalence of CDKL5 Deficiency Disorder in the 7MM (2019–2032)
-
Diagnosed Prevalent cases of CDKL5 Deficiency Disorder in the 7MM (2019–2032)
-
Clinical Manifestation Specific Prevalent cases of CDKL5 Deficiency Disorder in the 7MM (2019–2032)
-
Treated cases of CDKL5 Deficiency Disorder in the 7MM (2019–2032)
CDKL5 Deficiency Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the CDKL5 Deficiency Disorder market or expected to be launched during the study period. The analysis covers the CDKL5 Deficiency Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the CDKL5 Deficiency Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the CDKL5 Deficiency Disorder Market Will Evolve and Grow by 2032 @
CDKL5 Deficiency Disorder Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for CDKL5 Deficiency Disorder. Currently, UCB S.A. is leading the therapeutics market with its CDKL5 Deficiency Disorder drug candidates in the most advanced stage of clinical development.
The Leading Companies in the CDKL5 Deficiency Disorder Therapeutics Market Include:
-
UCB S.A.
-
Ultragenyx Pharmaceutical
-
Amicus Therapeutics
-
Ovid Therapeutics
-
REGENXBIO
And Many Others
CDKL5 Deficiency Disorder Therapies Covered in the Report Include:
-
Fenfluramine: UCB S.A.
-
Marinus Pharmaceuticals: Ganaxolone
-
Ovid Therapeutics/Takeda: Soticlestat
-
Zogenix: Fintepla (ZX008)
-
PTC Therapeutics: Translarna (ataluren)
-
TAK-935/OV935: Takeda and Ovid Therapeutics
-
Ganaxolone: Marinus Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. CDKL5 Deficiency Disorder Competitive Intelligence Analysis
4. CDKL5 Deficiency Disorder Market Overview at a Glance
5. CDKL5 Deficiency Disorder Disease Background and Overview
6. CDKL5 Deficiency Disorder Patient Journey
7. CDKL5 Deficiency Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)
8. CDKL5 Deficiency Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. CDKL5 Deficiency Disorder Unmet Needs
10. Key Endpoints of CDKL5 Deficiency Disorder Treatment
11. CDKL5 Deficiency Disorder Marketed Products
12. CDKL5 Deficiency Disorder Emerging Drugs and Latest Therapeutic Advances
13. CDKL5 Deficiency Disorder Seven Major Market Analysis
14. Attribute Analysis
15. CDKL5 Deficiency Disorder Market Outlook (In US, EU5, and Japan)
16. CDKL5 Deficiency Disorder Access and Reimbursement Overview
17. KOL Views on the CDKL5 Deficiency Disorder Market
18. CDKL5 Deficiency Disorder Market Drivers
19. CDKL5 Deficiency Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
, Asserts DelveInsight){kind=link}